Transcription-based drug repurposing for COVID-19.
Antiviral Agents
/ chemistry
COVID-19
/ virology
Drug Repositioning
Epithelial Cells
/ drug effects
Gene Expression Profiling
Humans
Lung
/ drug effects
Severe acute respiratory syndrome-related coronavirus
/ drug effects
SARS-CoV-2
/ drug effects
Transcriptome
/ drug effects
COVID-19 Drug Treatment
COVID-19
Gene expression
Repurposing
Journal
Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
25
08
2020
revised:
21
09
2020
accepted:
22
09
2020
pubmed:
29
9
2020
medline:
15
12
2020
entrez:
28
9
2020
Statut:
ppublish
Résumé
We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti-COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.
Identifiants
pubmed: 32987033
pii: S0168-1702(20)31083-2
doi: 10.1016/j.virusres.2020.198176
pmc: PMC7518800
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198176Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Références
Leukemia. 2018 Apr;32(4):882-889
pubmed: 29089643
Viruses. 2021 Apr 09;13(4):
pubmed: 33918958
Hypertension. 2014 Dec;64(6):1368-1375
pubmed: 25225202
Biochim Biophys Acta. 2016 Nov;1863(11):2624-2636
pubmed: 27496272
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13742-7
pubmed: 19666591
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Transl Psychiatry. 2019 Sep 6;9(1):220
pubmed: 31492831
Nat Med. 1998 Nov;4(11):1293-301
pubmed: 9809554
J Neuroinflammation. 2014 Dec 31;11:218
pubmed: 25551197
J Virol. 2017 Jan 18;91(3):
pubmed: 27881644
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1755-60
pubmed: 25624492
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
Arch Virol. 2006 Dec;151(12):2495-501
pubmed: 16932984
Cancer Cell. 2006 Oct;10(4):331-42
pubmed: 17010674
Front Pharmacol. 2012 Oct 04;3:176
pubmed: 23060796
Cell. 2013 Mar 14;152(6):1237-51
pubmed: 23498934
BMC Genomics. 2012 Jan 10;13:12
pubmed: 22233519
Pharmaceuticals (Basel). 2020 Mar 21;13(3):
pubmed: 32245264
Science. 1999 Oct 15;286(5439):531-7
pubmed: 10521349
Cell. 2000 Jul 7;102(1):109-26
pubmed: 10929718
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651